Samsung Biologics, a leading contract development and manufacturing organization (CDMO) and the prominent biotech arm of Samsung Group, has agreed to return to the negotiation table this week amidst an ongoing **labor strike**, a corporate official confirmed.
The crucial discussions between **Samsung Biologics** and its labor union are scheduled for Monday, under the mediation of the Jungbu regional employment and labor office. This follows the breakdown of initial talks held last Thursday, highlighting the urgent need for a resolution to the escalating **labor dispute**.
This marks the first-ever **labor strike** for the union, with the widespread **work stoppage** by **Samsung Biologics employees** having entered its third day by Sunday.
A company source stated, “Our decision to engage with the labor ministry’s arbitration request amidst the ongoing walkout underscores our genuine commitment to resolving this issue through constructive dialogue.” The representative further implored the **labor union** to reconsider what they termed “irrational” **demands** and **collective action**, urging an immediate return to productive **negotiations**.
Reports indicate that during the initial arbitration meeting last week, the **Samsung Biologics labor union** presented a significant precondition: the complete replacement of the company’s bargaining committee members before further talks could proceed.
**Unionized workers** at **Samsung Biologics** commenced their **strike action** on Friday, articulating a clear set of **demands**. These include a substantial 14 percent increase in both base and performance-related pay, a one-off cash incentive of 30 million won (approximately $20,389.9) per employee, and bonuses equivalent to 20 percent of the company’s annual operating profit. These **wage increase demands** are central to the current dispute.
In response, the company has put forth an offer comprising a combined 6.2 percent increase in base and performance pay, significantly lower than the union’s proposition for **employee pay**.
According to the **Samsung Biologics labor union**, approximately 2,800 of its 4,000 unionized members have actively participated in this **collective action**, impacting operations at the company’s facilities, including its prominent **Incheon factory** in west Seoul.
The company projects significant financial repercussions from the **work stoppage**, estimating potential damages of at least 640 billion won. This figure is substantial, representing roughly half of **Samsung Biologics**’ total sales for the first quarter, underscoring the high stakes of the ongoing **labor dispute** within the **biotech industry**.
The **labor union** has affirmed its intention to continue the **strike** until Tuesday, indicating a firm stance unless their **demands** are met.
Beyond **wage increases**, the **unionized workers** of **Samsung Biologics** are also advocating for the establishment of “fair and transparent” **personnel management standards**. In a recent release, the **labor union** articulated this as a fundamental demand: “What the labor union demands is that the management should exercise personnel and management authority in a transparent manner so that the employees can work while trusting the company.” This highlights a deeper concern regarding corporate governance and employee trust at the **biotech giant**.
